BRAF V600E与Langerhans细胞组织细胞增生症（Langerhans cell histiocytosis）成年患者的二次恶性肿瘤发生率增高相关。
BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis.
发表日期：2023 Aug 18
作者：
Aldo A Acosta-Medina, Paul Geraeds Kemps, Timo Ce Zondag, Jithma P Abeykoon, Jelske Forma-Borst, Eline Christine Steenwijk, Elizabeth A M Feijen, Jop C Teepen, N Nora Bennani, Susan M Schram, Mithun Vinod Shah, Caroline Davidge-Pitts, Matthew J Koster, Jay Ryu, Robert Vassallo, W Oliver Tobin, Jason R Young, Surendra Dasari, Karen L Rech, Aishwarya Ravindran, Arjen Hg Cleven, Robert M Verdijk, Carel J M van Noesel, Brian V Balgobind, Gerrit J Bouma, Peerooz Saeed, Jos A M Bramer, Ruben Al de Groen, Joost S P Vermaat, Michiel A J van de Sande, Egbert F Smit, Anton W Langerak, Tom van Wezel, Sanne H Tonino, Cor van den Bos, Jan Am van Laar, Ronald S Go, Gaurav Goyal, Astrid G S van Halteren
来源：
BLOOD
摘要：
在这项回顾性研究中，对156名LCH成年患者进行的分析发现，BRAF突变状态与疾病范围或（无事件）生存率没有相关性。BRAFV600E突变与第二次恶性肿瘤的发生率增加有关，其中往往包括血液肿瘤，可能存在克隆相关性。© 2023美国血液学会。
In this retrospective study, BRAFmutation status did not correlate with disease extent or (event-free) survival in 156 adults with LCH. BRAFV600E was associated with an increased incidence of second malignancies, often comprising hematological cancers - which may be clonally related.Copyright © 2023 American Society of Hematology.